Clinical Trial Update: A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated four doses of imeglimin over 24 weeks in adults with Type 2 Diabetes Mellitus. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Imeglimin (imeglimin)

Snippet

Sponsor: Poxel SA | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED